J&J reports Q2 sales of $25.3B (+6.6%), raises 2026 guidance to $101.1B revenue and $11.68 EPS

Filed July 15, 2026 · Period ending July 15, 2026 · ~2 min read

Key Changes

• high

  Q2 2026 sales reached $25.3B (+6.6% YoY, +5.6% operational), with adjusted EPS of $2.90 (+4.7% YoY). Innovative Medicine grew 7.8% driven by oncology (DARZALEX +20.7%, CARVYKTI +31.7%) and TREMFYA (+84.2%), partially offset by STELARA's 68.8% U.S. decline from biosimilar competition.

  Exhibit 99.1 view on EDGAR →
• high

  Full-year 2026 guidance raised to $101.1B revenue (7.3% growth at midpoint, up from $100.8B prior) and adjusted EPS of $11.68 (8.2% growth, up $0.13). Adjusted operational EPS increased $0.18 to $11.58 (7.3% growth).

  Exhibit 99.1 view on EDGAR →
• high

  MedTech segment sales grew 4.5% to $8.9B, led by Cardiovascular (+8.3%, including Shockwave +14.6% and Electrophysiology +8.3%), Surgery (+4.3%), Vision (+6.3%), and Orthopaedics (+5.6%).

  Exhibit 99.2 view on EDGAR →